SCHEMBL2270702

SCHEMBL2270702

CCCCCCOc1cccc(C(=O)O)n1.[Zn]

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
PLA2G4B P0C869 3/20 0.47
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46
ACMSD Q8TDX5 1/20 0.46
RARB P10826 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PLA2G2A P14555 1/20 0.44
SOAT1 P35610 1/20 0.44
PTPN11 Q06124 1/20 0.43
PLA2G4A P47712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9094639 0.98 TSHR (0.49) TSHRTP53PLA2G4BTDP1KDM4E
SCHEMBL2270674 0.94 KDM4E (0.48) TSHRTP53PLA2G4BTDP1KDM4E
SCHEMBL2460027 0.92 KDM4E (0.50) TSHRTP53PLA2G4BTDP1KDM4E
SCHEMBL22835984 0.85 KDM4E (0.48) TSHRTDP1KDM4EALOX15ACMSD
Zinc Ion SCHEMBL9440334 0.84 PTGER1 (0.45) TSHRTP53PLA2G4BMEN1KMT2A
SCHEMBL8583652 0.84 SOAT1 (0.51) TSHRTP53PLA2G4BSOAT1
SCHEMBL29502408 0.83 KDM4E (0.50) TSHRTDP1KDM4EALOX15ACMSD
SCHEMBL22835305 0.83 KDM4E (0.50) TSHRTDP1KDM4EALOX15ACMSD
SCHEMBL8265156 0.82 KDM4E (0.48) TSHRTDP1KDM4EALOX15ACMSD
SCHEMBL29683116 0.81 MAPK8 (0.55) TSHRTDP1KDM4EALOX15ACMSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) 2006-07-06 US disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
CN-1466454-A Method for treating symptoms of common cold, allergic rhinitis and respiratory tract related infections ���·�ķ��˾ 2004-01-07 CN disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed
EP-0433457-B1 ANTIPRURITIC COMPOSITION SHISEIDO CO LTD (JP) 1994-10-19 EP disclosed
US-5219847-A Antipruritic composition SHISEIDO COMPANY, LTD. (JP) 1993-06-15 US disclosed
EP-0433457-A1 ANTIPRURITIC COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol CHIA, MAVS, C1QBP TSHR 4733/4885TP53 174/4885PLA2G4B 4055/4885
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TSHR 3718/4885TP53 3601/4885PLA2G4B 2512/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TSHR 3718/4885TP53 3601/4885PLA2G4B 2512/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP TSHR 4733/4885TP53 174/4885PLA2G4B 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.